-
关于我们
Proji Company was founded in August 2004. It is a high-tech research and development enterprise established by returned overseas students, undertaking the task of industrializing and transforming various scientific research projects. -
Scientific research technology
Scientific research technology
科研技术
Proji Company is a constituent unit of the "National Engineering Research Center for Protein Technology" of Tsinghua University. It is the first national engineering laboratory established by the National Development and Reform Commission at Tsinghua University. Former President of the Chinese Academy of Sciences, Zhou Guangzhao, and the "Father of DNA", Nobel laureate James D. Watson served as honorary directors of the laboratory, with Professor Luo Yongzhang serving as the director. -
Products
公司产品
For nearly two decades, Proji Company has been primarily engaged in the development and production of recombinant protein drugs, antibody drugs, and in-vitro diagnostic reagents. It has established a unique R&D and large-scale preparation technology platform for recombinant protein drugs that has reached international standards. -
Project
项目公司
The company has long received strong support from various levels of government, including the National Development and Reform Commission, the Ministry of Science and Technology, and the municipal governments of Beijing, Yantai, Shenzhen, and Changzhou. -
新闻资讯
The company's marketing network spans 18 provinces and cities across the country (including 6 provinces and cities covered by medical insurance), benefiting more than 4 million patients, and gradually growing into a new benchmark in the biopharmaceutical industry. -
职业发展
From small-scale research institutions to advanced biopharmaceutical bases, the company's marketing network spans 18 provinces and cities across China.
Shenzhen Protgen Announces Publication of Phase 3 Clinical Trial Results for Recombinant Human Serum Albumin (PG-rHSA) in STTT
Published Time:
2026-09-19 15:20
SHENZHEN, September 19, 2026 — Shenzhen Protgen Co., Ltd. ("Shenzhen Protgen") today announced that the Phase 3 clinical trial and molecular evaluation of its investigational Recombinant Human Serum Albumin (PG-rHSA) for the treatment of cirrhotic ascites have been published in Signal Transduction and Targeted Therapy (STTT).
Sponsored by Shenzhen Protgen, this nationwide, multicenter, randomized, double-blind, active-controlled Phase 3 study evaluated the clinical performance of PG-rHSA relative to plasma-derived human serum albumin (pHSA) in patients with cirrhotic ascites and hypoalbuminemia.
Key findings include:
- Primary Endpoint: PG-rHSA demonstrated statistical equivalence to pHSA in raising serum albumin levels.
- Secondary Endpoint: PG-rHSA achieved non-inferiority in ascites improvement rate relative to the control group.
- Safety: The overall incidence of adverse events was comparable between arms, with no drug-related immunogenicity signals observed.
The New Drug Application (NDA) for PG-rHSA has been officially accepted by the CDE of the National Medical Products Administration (NMPA), and is currently undergoing formal regulatory review.
Article DOI: 10.1038/s41392-026-02951-7
Previous Page
Related Recommendations
Beijing Protgen Biotechnology Development Co., Ltd.
Tel:86010- 6297 9258
Postcode: 100085
Email:protgen@protgen.com
Address: No. 32, Chuangye Zhonglu, Haidian District, Beijing
Official Account QR Code
Maintenance Department QR Code
copyright © 2024 Beijing Progen Biotechnology Development Co., Ltd. Powered by：CEglobal TagsFriendly Links:Tsinghua UniversityNEC